Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated December 14, 2017, reports on events occurring on December 13, 2017, for Cellect Biotechnology Ltd. (also referenced as Quoin Pharmaceuticals, Ltd. in metadata). The filing documents the results of an Extraordinary General Meeting of Shareholders where all proposed agenda items were approved.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity compensation matters.
Material Changes and Corporate Actions
- Director Elections: David Braun was elected as a director until the next annual general meeting. Ruhama Avraham was elected as an external director for a three-year term ending December 12, 2020, with additional service on the audit and compensation committees.
- Equity Grants to New Directors:
- David Braun and Ruhama Avraham were each granted 150,000 options to purchase ordinary shares (represented by 7,500 ADSs).
- Exercise price: NIS 1.437 per option.
- Vesting: 25% on December 12, 2018, with the balance vesting quarterly (6.25% per quarter) over four years. Vesting accelerates in a change of control.
- Expiration: 10 years from issuance.
- Equity Grant to Existing Director:
- Yuval Berman, an external director, was granted 78,000 options to purchase ordinary shares (represented by 3,900 ADSs).
- Exercise price: NIS 1.437 per option.
- Vesting: 25% on February 28, 2017, with the balance vesting quarterly thereafter over four years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of shareholder meeting outcomes and director compensation.
Key Facts for Investor Verification
- Verify the total number of outstanding options and the potential dilution impact of the 378,000 new options granted to directors.
- Confirm the current share price relative to the NIS 1.437 exercise price to assess the intrinsic value of the grants.
- Review the biographies of David Braun and Ruhama Avraham to evaluate their specific expertise relative to the company's strategic needs.
- Check subsequent filings for the company's financial performance, as this 6-K contains no financial data.